Factor XIII-dependent generation of 5th complement component(C5)-derived monocyte chemotactic factor coinciding with plasma clotting.
Blood coagulation or plasma clotting caused generation of a monocyte chemotactic factor(s) in vitro. The chemotactic factor, of which the apparent molecular mass was 75 kDa, shared antigenicity with complement C5 and possessed the affinity to monocytes, but not to polymorphonuclear leukocytes. The generation of the chemotactic factor was hindered in the presence of a thiol enzyme inhibitor, p-chloromercuriphenyl sulfonic acid, at the concentration of 1 mmol/l, although the gelation of plasma was apparently completed. Furthermore, the generation of chemotactic factor was not observed when a plasma deficient in blood coagulation factor XIII, which is a precursor of a thiol enzyme, plasma transglutaminase, was used; and the activity normally appeared when the deficient plasma was reconstituted with purified factor XIII or with a tissue transglutaminase prior to clotting. When the human sera were injected into guinea pig skin, the serum derived from normal plasma or from the reconstituted factor XIII deficient one caused mononuclear cell infiltration, however, the serum from the deficient plasma without reconstitution infiltrated to a significantly smaller extent. These results indicated that the complement system was initiated somehow during the clotting process resulting in the generation of the C5-derived monocyte chemotactic factor in cooperation with factor XIIIa (activated factor XIII).
Okamoto
M
M
First Department of Surgery, Kumamoto University Medical School, Japan.
Yamamoto
T
T
Matsubara
S
S
Kukita
I
I
Takeya
M
M
Miyauchi
Y
Y
Kambara
T
T
D000818:Animals; D001777:Blood Coagulation; D016764:Cell Polarity; D002630:Chemotactic Factors / Q000096:biosynthesis* / Q000302:isolation & purification; D003182:Complement C5 / Q000378:metabolism*; D005176:Factor XIII / Q000494:pharmacology*; D005177:Factor XIII Deficiency / Q000097:blood; D006168:Guinea Pigs; D006801:Humans; D007164:Immunosorbents; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D010663:Phenylmercury Compounds / Q000494:pharmacology; D012867:Skin / Q000276:immunology*; D011503:Transglutaminases / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014945:Wound Healing / Q000276:immunology*
D002630:Chemotactic Factors; D003182:Complement C5; D007164:Immunosorbents; D010663:Phenylmercury Compounds; D005176:Factor XIII; D011503:Transglutaminases